Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer

Hyunsoo Chung1*, Hanbyoul Cho2*, Candice Perry1, Jaekyung Song2, Kris Ylaya1, Heejeong Lee3, and Jae-Hoon Kim2

1Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, 2Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea, and 3Department of Pathology, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

Abstract

Objective: We investigated the clinical significance of ERp57 in the progression of cervical cancer.

Methods: mRNA and protein expression of ERp57 in cervical neoplasias were examined.

Results: ERp57 mRNA expression was significantly decreased in cervical cancers. Immunohistochemistry revealed that ERp57 expression in 123 cervical cancers was downregulated compared to cervical intraepithelial neoplasias or normal tissues (p < 0.001). Low ERp57 expression was significantly associated with worse overall survival (HR = 12.19, p = 0.018).

Conclusions: Low ERp57 expression independently predicts a poor outcome for patients with cervical cancer, supporting the notion that ERp57 may be a promising novel cancer target.

Keywords

Cervical cancer, ERp57, immunohistochemistry, survival, tissue microarray

Introduction

Cervical cancer is one of the most common gynecologic tumors worldwide and is a leading cause of female cancer-related death in developing countries (Moody et al., 2010). According to official statistics, more than 50% of all cases and deaths from the disease worldwide were reported in the Asia Oceania region, with the highest incidence and mortality rates in South Central and Southeast Asia (Garland et al., 2012). The high mortality is ascribed to disease recurrence after cervix resection and lack of effective treatment for advanced stage disease (Chun, 2009). Although many clinicopathological factors have been described as prognostic tools, a limited number of these parameters have been incorporated and used in the clinic. Furthermore, molecular markers that accurately predict response to therapy are limited because of their low sensitivity and specificity. Therefore, it is necessary to identify reliable molecular markers predictive of the clinical outcome of patients with cervical cancer.

ERp57, the protein encoded by the PDIA3 on chromosome 15, is a glycoprotein-specific thiol-oxidoreductase and a component of the protein disulfide isomerase (PDI) family that is involved in the major histocompatibility complex (MHC) I antigen processing molecules (Lindquist et al., 1998). The role of the MHC class I molecule is to present small peptides to cytotoxic T lymphocytes (Radcliffe et al., 2002), which can potentially trigger a cascade of immune responses. Defective component expression of the MHC class I antigen processing complex is hypothesized to be an important mechanism of MHC class I downregulation and can lead to immune evasion by tumor cells. Defects in MHC class I expression have been found in many tumor types and are associated with advanced stage and poor survival in patients with cancer (Atkins et al., 2004; Mehta et al., 2008; Ogino et al., 2003).

Because ERp57 has an important role in antigen processing, the regulation of ERp57 protein expression may be associated with human diseases including cancer. Tumor cells utilize impaired antigen presentation as one immune escape mechanism that results in the progression of tumorigenesis (Igney et al., 2002). For example, downregulation or loss of MHC class I antigens has been found in many types of tumors and is associated with an adverse prognosis (Atkins et al., 2004; Ogino et al., 2003; Seliger et al., 2000). Furthermore, loss of ERp57 protein expression has been reported to be associated with poor prognosis in gastric cancer and head and neck cancer (Leys et al., 2007; Ogino et al., 2003). Despite evidence supporting ERp57 involvement in tumorigenesis, the relationship between ERp57 expression and clinicopathological factors in various human cancers, including cervical cancer, remains unclear.

*These authors contributed equally to this work.

Address for correspondence: Jae-Hoon Kim, Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, 146-92 Dogok-Dong, Gangnam-Gu, Seoul, Korea. Tel: +82-2-3462-8209. E-mail: jaehoonkim@yuhs.ac; Heejeong Lee, Department of Pathology, Bucheon St. Mary’s Hospital, The Catholic University of Korea, 327 Sosaro, Wonmi-Gu, Bucheon, Gyeonggi-Do 420-717, Korea. Tel: +82-32-340-7092. Fax: +82-32-340-2219. E-mail: heejeung@catholic.ac.kr
In this study, we investigated the mRNA level of ERp57 in cervical cancer cells, cancer tissues and normal cervical epithelial tissues. Additionally, we studied the subcellular localization of ERp57 in CaSki cells by Western blotting combined with subcellular fractionation. To evaluate the potential relationship between ERp57 and various clinicopathological parameters, we analyzed ERp57 protein expression in a large series of cervical cancer, precursor and corresponding normal tissues, and demonstrated that ERp57 expression levels are altered during cervical carcinogenesis and down-regulation of ERp57 is correlated with poor prognosis.

Materials and methods

Patients and specimens

After gaining institutional review board approval, 123 paraffin-embedded cervical cancer, 187 cervical intraepithelial neoplasia (CIN) and 310 matched normal cervix tissues that had been resected at Gangnam Severance Hospital, Yonsei University College of Medicine between 1996 and 2010 were retrieved. Some of the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Korea Ministry of Education, Science and Technology. All tumor tissues were histologically revised and only specimens with sufficient tumor cells were included in the tissue microarray (TMA) construction. Tumor staging was performed according to the International Federation of Gynecology and Obstetrics (FIGO) classification system.

Primary treatment for stage I/II consisted of type II or III radical hysterectomy with pelvic lymph node (LN) dissection. In cases of increased risk of relapse including positive resection margins, parametrial invasion, or positive LN metastasis, platinum-based concurrent chemoradiation was added as adjuvant therapy. Patients with inoperable disease or metastasis, platinum-based concurrent chemoradiation was performed according to the International Federation of Gynecology and Obstetrics (FIGO) classification system.

Western blotting

CaSki cells were cultured, harvested and fractionated with the NE-PER Nuclear and Cyttoplasmic extraction kit according to the manufacturer’s protocol (NE-PER Reagents, Thermo Scientific, Rockford, IL). Ten micrograms of the cellular fractions were separated by 4–12% SDS-PAGE and transferred to a nitrocellulose membrane. After blocking for one hour with 5% nonfat milk in TBST (50 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.5), the membrane was washed with TBST and then incubated overnight at 4°C with polyclonal rabbit anti-ERp57 (1:500; Santa Cruz Biotechnology), Subsequently, the membrane was washed with TBST and incubated with anti-mouse or rabbit conjugated to horseradish peroxidase (1:5000; Millipore, Billerica, MA) for two hours. The signal was detected using a SuperSignal Chemiluminescence kit (Thermo Scientific).

Tissue microarray (TMA) construction and immunohistochemical staining

TMAs were constructed from archival formalin-fixed, paraffin-embedded tissue blocks, as previously described (Noh et al., 2012). Briefly, for each tumor and matched normal epithelial tissue, a representative area was carefully selected from a hematoxylin and eosin (H&E) stained section of the donor block, cored and placed into the recipient array block using a 1.0-mm needle.

For immunohistochemical staining, 5-µm paraffin sections were incubated at 60°C for two hours, deparaffinized in xylene and hydrated in serial alcohol solutions to distilled water for five minutes each. Heat antigen retrieval was performed by submerging slides in pH 6 citrate buffer at 121°C for 15 minutes using a pressure cooker (DAKO, Carpinteria, CA) and blocking in 1% skim milk for 30 minutes. Endogenous enzyme activity was inhibited with 3% hydrogen peroxide containing sodium azide for an additional
Patients ranged in age from 21 to 79 years (mean, 42.6 years). The mean ages were 39.3 ± 10.3 years for low-grade CIN, 38.4 ± 11.0 years for high-grade CIN and 48.8 ± 11.4 years for cervical cancer. There was a significant age difference between low- or high-grade CIN and cancer patients (p < 0.001, respectively). However, ERp57 expression did not correlate with patient age, but was similar in all age groups (Spearman’s ρ = −0.068, p = 0.233). Patient clinical characteristics are detailed in Table 1. Tumor grade data was available for 119 cases, and 4 cases (3.4%) were well, 80 cases were moderate (67.2%), and 35 cases were poor (29.4%). FIGO staging was available for all 123 cases: 89 cases were stage I (72.3%) and 34 cases were stage II (27.7%). There were 96 squamous cell carcinomas (78.0%), 22 adenocarcinomas/adenosquamous carcinomas (17.9%), 4 small cell carcinomas (3.3%) and 1 clear cell carcinoma (0.8%). Follow-up duration ranged from 5 to 60 months, with a mean of 37.8 months. The HC2-based HPV infection rate was 76.5% (26/34) in low-grade CIN, 88.9% (96/108) in high-grade CIN and 95.3% (61/64) in cervical cancer.

### mRNA expression and subcellular localization of ERp57

The ERp57 expression levels were significantly lower in cancer cell lines (mean $2^{-ΔΔCt} = 0.36$, p = 0.014) and tumor-bearing cancer tissues (mean $2^{-ΔΔCt} = 0.89$, p = 0.013) compared with normal cervical epithelial tissues (mean $2^{-ΔΔCt} = 8.89$), reflecting low ERp57 mRNA expression in cancer cell lines (24.7-fold) and tissues (9.9-fold) (Figure 1a). To examine the specificity and capability of anti-ERp57 antibodies, we subsequently investigated the level of ERp57 protein in CaSki cells by Western blotting. Western blot analysis of the cultured cervical cancer cultured cells revealed a clear single band around 60 kDa corresponding to ERp57.
to ERp57 (Figure 1b). Although ERp57 was detected in both cytosolic and nuclear fractions, high expression was restricted to cytosolic fractions (Figure 1b). The purities of the cytosolic and nuclear fractions were respectively confirmed with Calnexin and Lamin B1.

Association between ERp57 expression and clinicopathological characteristics

As shown in Figure 2, positive staining for ERp57 protein was located primarily in the cytoplasm of tumor and normal epithelial cells. Expression was higher in normal cervical epithelial tissue and low-grade CIN specimens than in high-grade CIN and cancer tissues \( (p < 0.001) \) (Table 1). This trend of progressively lower ERp57 protein expression corresponding to the phases of cervical cancer progression was significant by Spearman’s rank correlation \( (p \text{ value of } -0.589, p < 0.001) \). In addition, ERp57 immunoreactivity significantly correlated with tumor grade \( (p < 0.001) \) and cell type \( (p = 0.004) \) (Figure 3).

Prognostic significance of ERp57 expression

The mean follow-up period was 37.89 months \( (95\% \ CI, 34.16–41.63) \). By the end of follow-up, 16 patients \( (13.0\%) \) had died of cervical cancer, and recurrence or persistent disease was reported in 15 patients \( (12.2\%) \). Kaplan–Meier plots demonstrated that patients with FIGO stage II and low ERp57 expression \( (\text{histoscore} \leq 6) \) had significantly worse disease-free survival \( (p < 0.001 \text{ and } p = 0.029, \text{respectively}) \) (data not shown), and patients with low ERp57 expression also showed significantly worse overall survival \( (p = 0.019) \) (Figure 4). Cox multivariate proportional hazards analysis showed that low ERp57 expression \( \text{[hazard ratio} = 12.19 \ (95\% \ CI, 1.75–36.10), \ p = 0.018\] \) and non-SCC cell type \( \text{[hazard ratio} = 4.33 \ (95\% \ CI, 1.57–11.91), \ p = 0.005\] \) were independent prognostic factors for overall survival.

Discussion

ERp57 has been found in many different subcellular locations and it is involved in a remarkable variety of processes. One of the widely studied functions of ERp57 is its role in the assembly of MHC class I antigen processing (Lindquist et al., 2001). The glycosylated heavy chain of MHC class I binds to both calnexin and ERp57, and this complex oxidizes the heavy chain through disulfide bond formation. The oxidized heavy chain allows assembly of soluble subunit \( \beta_2\)-microglobulin and subsequently contributes to the formation of the MHC class I peptide-loading complex (Garbi et al., 2006). This complex is composed of heavy chain class I protein, \( \beta_2\)-microglobulin, calreticulin, ERp57, tapasin and the trans-transporters associated with antigen presentation (TAPs). It has recently been reported that the level of \( ERp57 \) gene promoter methylation was significantly higher in CIN and cervical cancer cases in comparison to normal tissues. In addition, the high level of \( ERp57 \) methylation was correlated with human papillomavirus 16 positivity in human cervical cancer cases (Hasim et al., 2012). Therefore, ERp57 may be linked to cancer progression by an unknown mechanism.

To gain some insight into the timing of ERp57 down-regulation during tumor development, we studied ERp57 expression in low- and high-grade CIN, both of which are considered premalignant lesions, and in invasive cervical cancer. IHC analysis revealed a drastic reduction in ERp57 protein expression in high-grade CIN \( (\text{mean histoscore} = 6.81) \) and invasive cervical carcinoma \( (\text{mean} = 5.75) \) specimens compared to normal tissues \( (\text{mean} = 10.79) \). This finding suggests that ERp57 may play an important role in cervical carcinogenesis.
As an MHC class I peptide-loading complex component, ERp57 is important for T-cell-mediated anti-tumor or antiviral immunity. Few studies have investigated the expression and distribution of ERp57 in tumors in addition to its clinical significance. Mehta et al. previously reported a 28–60% loss of ERp57 expression depending on histological type. They suggested that downregulation of ERp57 was significantly associated with HLA class I downregulation, a potential contributor to tumor progression (Mehta et al., 2008). Recently, Hasim and colleagues analyzed the association of cervical carcinogenesis with the aberrant regulation of HLA class I and expression of antigen processing machinery components including ERp57 (Hasim et al., 2012). They immunohistochemically examined the expression

Figure 2. Representative ERp57 immunohistochemical staining images of formalin-fixed paraffin-embedded uterine cervix tissues on tissue microarrays show strong positive diffuse granular cytoplasmic staining in normal cervical epithelial tissue (a), weak to moderate cytoplasmic staining for low- (b) and high-grade (c) CIN and an absence of staining in cervical cancer specimens (d). The subcellular distribution is dominantly cytoplasmic and no definite nuclear staining pattern is noted. Bars: 200 μm.

Figure 3. IHC staining scores for ERp57 in cervical neoplasm samples. IHC staining scores for ERp57 in high-grade CIN, cervical cancer and metastasis specimens were significantly lower than that in normal controls (a). ERp57 expression was significantly decreased in poorly differentiated (b) and squamous cell carcinomas (c).
of ERp57 in cervical lesions (64 CINs and 63 SCCs) and detected a loss of ERp57 expression in both CIN (42%) and SCC (56%). They also reported that ERp57 protein expression was significantly lower in lower stage tumors than in higher stages and it was inversely correlated with tumor differentiation. Consistent with previous studies, we found that ERp57 expression decreased according to the progression of cervical tumorigenesis ($p < 0.001$) and was significantly stronger in well and moderately differentiated tumors in comparison with poorly differentiated ones ($p < 0.001$). However, in contrast to their study, there was no significant difference in ERp57 expression between FIGO stages I and II. This discrepancy may be explained by a lack of standardized immunohistochemical methods, different standards of interpretation, small number of examined cases and/or a different disease spectrum in the cases studied.

With regard to different cancer cell types, the fact that ERp57 expression was significantly lower in squamous cell carcinomas (mean histoscore = 5.31) compared with non-SCC types (mainly adenocarcinoma/adenosquamous carcinomas; 81.5%, 22 out of 27) (mean histoscore = 7.30) was a finding of interest, as it suggests that the two aforementioned carcinomas can be distinguished based on genetic alterations. Furthermore, this finding demonstrates that each histologic type of cervical cancer develops via a distinct molecular mechanism. Consistent with our findings, Mehta et al. reported a higher frequency of ERp57 expression loss in squamous cell carcinomas (60%, 45 out of 76) compared with adenocarcinomas (28%, 7 out of 25) in their IHC study HLA class I loss in cervical carcinomas (Mehta et al., 2008). These findings suggest that each histologic type of cervical cancer could develop independently, and further studies are needed to identify the molecular genetic changes and percentage of ERp57 downregulation according to cell type. We also included HPV infection status in our analysis and observed no statistical difference between the expression of ERp57 in HPV-positive and -negative patients. Whether ERp57 expression is directly regulated by high-risk HPV remains unclear.

Our most notable finding is that low expression of ERp57 in cervical cancer predicts a shorter disease-free and overall survival. To our knowledge, the negative influence of ERp57 expression on the prognosis of cervical carcinoma patients has not been described previously. Multivariate Cox hazard analysis indicated that low ERp57 expression, large tumor size and LN metastasis are significantly associated with poorer disease-free survival in cervical cancer patients. Moreover, low ERp57 expression and non-SCC cell type were independent prognostic factors for overall survival on
multivariate analysis. Consistent with our findings, Leys et al. demonstrated that a loss of ERp57 expression was associated with tumor invasion and poor survival in an IHC study of 164 gastric cancer patients (Leys et al., 2007). Thus, given the role of ERp57 in the assembly of the MHC class I antigen processing complex, these findings suggest that downregulation of ERp57 may contribute to more aggressive tumor behavior. Furthermore, this study supports the notion that low ERp57 expression could serve as a novel and independent predictor of recurrence and death in early-stage cervical cancer patients. Because downregulation of ERp57 was an independent predictor of poor survival in early-stage disease, one can therefore infer that evaluation of ERp57 in patients with early-stage disease might be of significant value in identifying individuals who would benefit from more aggressive post-operative adjuvant therapies.

In conclusion, this is the first study to find that ERp57 expression is associated with the progression of cervical carcinogenesis, with a gradual reduction in the order of progression from normal epithelium to CIN to cancer. We also discovered important correlations between the downregulation of ERp57 and clinicopathological parameters that might be potentially useful clinically. Moreover, we suggest that downregulation of ERp57 expression is an independent predictor of poor prognosis in early-stage cervical cancer.

Declaration of interest

No potential conflicts of interest were disclosed.

This work was supported in part by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0005230, 2011-0010286, and 2011-0007146), and faculty research grants from Yonsei University College of Medicine for 2010 and 2011 (3-2010-0072 and 6-2011-0073).

References

Atkins D, Ferrone S, Schmahl GE, et al. (2004). Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol 171:885–9

Chan M. (2009). Time for global efforts with clinical trials for advanced cervical cancer patients. J Gynecol Oncol 20:201–2.

Garbi N, Tanaka S, Momburg F, Hammerling GJ. (2006). Impaired assembly of the major histocompatibility complex class I peptide-loading complex in mice deficient in the oxidoreductase ERp57. Nat Immunol 7:93–102.

Garland SM, Bhatia N, Ngan HY. (2012). Cervical cancer burden and prevention strategies: Asia Oceania perspective. Cancer Epidemiol Biomarkers Prev 21:1414–22.

Hasim A, Abudula M, Aimiduo R, et al. (2012). Post-transcriptional and epigenetic regulation of Antigen Processing Machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One 7:e44952.

Igney FH, Krammer PH. (2002). Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 71:907–20.

Kirkegaard T, Edwards J, Tovey S, et al. (2006). Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–94.

Leys CM, Nomura S, LaFleur BJ, et al. (2007). Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141:41–50.

Lindquist JA, Hammerling GJ, Trowsdale J. (2001). ER60/ERp57 forms disulfide-bonded intermediates with MHC class I heavy chain. FASEB J 15:1448–50.

Lindquist JA, Jensen ON, Mann M, Hammerling GJ. (1998). ER-60, a chaperone with thiol-dependent reductase activity involved in MHC class I assembly. EMBO J 17:2186–95.

Livak KJ, Schmitthen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–8.

Mehta AM, Jordanova ES, Kenter GG, et al. (2008). Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206.

Moody CA, Laimins LA. (2010). Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10:550–60.

Noh KH, Kim BW, Song KH, et al. (2012). Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 122:4077–93.

Ogino T, Bandoh N, Hayashi T, et al. (2003). Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9:4043–51.

Radcliffe CM, Diedrich G, Harvey DJ, et al. (2002). Identification of specific glycoforms of major histocompatibility complex class I heavy chains suggests that class I peptide loading is an adaptation of the quality control pathway involving calreticulin and ERp57. J Biol Chem 277:46415–23.

Seliger B, Wollscheid U, Momburg F, et al. (2000). Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. Tissue Antigens 56:327–36.